During the manufacturing of an API, well-established purification is crucial for achieving high purity and yield, and at the same time is a major determinant for the cost efficiency and process productivity. Often, product purity comes at the expense of yield in conventional processes. Finding a good purification procedure represents a major challenge during API process development. Complicated purification requires more time and solvent. By finding new, innovative methods of improving side-fraction re-purification at large scale, API manufacturing will become cost-efficient, fast, and sustainable. It has been shown that Multicolumn Countercurrent Solvent Gradient Purification (MCSGP) achieves higher productivity and yield than single-column batch processes. This innovative purification process leads to time savings, economic advantages and a lower environmental footprint.

Ralf Eisenhuth

Process Manager Chromatography and Technology Transfer

Ralf Eisenhuth received his Ph.D. in organic synthesis from the University of Karlsruhe with a specialization in nucleoside and oligonucleotide synthesis. Ralf joined Bachem in 2008 as a team leader in API

manufacturing. Since then, he has worked in various positions, including Director of the Department of Large-Scale Purification at Bachem in Bubendorf. In his current position, he is the Process Manager, Chromatography and Technology Transfer. There, his main interests are new technologies and intensification of existing processes.

Daniel Samson

Vice President, Head Oligonucleotides

Daniel brings 15 years of industry experience to the team, with an emphasis on TIDES Process R&D, manufacturing, and CMC development. He leads Bachem’s oligonucleotide unit, including innovation projects,

R&D, and manufacturing activities. Daniel holds a PhD in organic chemistry from the University of Konstanz and an MBA from the International Institute for Management Development (IMD), Lausanne. In previous stages of his career, he was a lab head for process optimization, technology transfer, quality by design, and scale-up of synthetic peptide manufacturing procedures. From 2012, Daniel was the Vice President of API Manufacturing and had full responsibility for all large-scale solid-phase peptide and oligonucleotide syntheses, downstream operations, and CMC activities within Bachem AG. On March 1, 2022, Daniel assumed a new position as Vice President, Head Oligonucleotides at Bachem.

About Bachem:

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US, and Asia. The company is listed on the SIX Swiss Exchange.